Effects of levodopa on endocannabinoid levels in rat basal ganglia: Implications for the treatment of levodopa-induced dyskinesias

European Journal of Neuroscience

Volumn 18, Issue 6, 2003, Pages 1607-1614

  Ferrer, Belen ^a   Asbrock, Nick ^b   Kathuria, Satish ^b   Piomelli, Daniele ^b   Giuffrida, Andrea ^c  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

2 arachidonylglycerol; 6 hydroxydopamine; Anandamide; Cannabinoid; Fatty acid ethanolamides

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; OXIDOPAMINE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN LEVEL; CAUDATE NUCLEUS; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DYSKINESIA; GLOBUS PALLIDUS; INVOLUNTARY MOVEMENT; ISOTOPE DILUTION ASSAY; MALE; MOUTH; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TONGUE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; ENDOCANNABINOIDS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; LEVODOPA; MALE; MORPHOLINES; MOUTH; NAPHTHALENES; OXIDOPAMINE; PARKINSON DISEASE; PIPERIDINES; PYRAZOLES; RACLOPRIDE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 0141481993     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2003.02896.x     Document Type: Article

References (75)

1. Abercrombie, E.D., Bonatz, A.E. & Zigmond, M.J. (1990) Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res., 525, 36-44.
2. Aizman, O., Brismar, H., Uhlen, P., Zettergren, E., Levey, A.I., Forssberg, H., Greengard, P. & Aperia, A. (2000) Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nature Neurosci., 3, 226-230.
3. Anderson, L.A., Anderson, J.J., Chase, T.N. & Walters, J.R. (1995) The cannabinoid agonist Win 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res., 691, 106-114.
4. 2-receptor responses by an anandamide transport inhibitor. J. Neurosci., 20, 3401-3407.
5. Bezard, E., Brotchie, J.M. & Gross, C.E. (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Rev. Neurosci., 2, 577-588.
6. Bordet, R., Ridray, S., Carboni, S., Diaz, J., Sokoloff, P. & Schwartz, J. (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl Acad. Sci. USA, 94, 3363-3367.
7. Bordet, R., Ridray, S., Schwartz, J.-C. & Sokoloff, P. (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci., 12, 2117-2123.
8. Brooks, D.J. (2000) PET studies and motor complications in Parkinson's disease. Trends Neurosci., 23, S101-S108.
9. Brotchie, J.M. (2000) The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann. Neurol., 47, S105-S114.
10. 1 cannabinoid receptor signalling in Parkinson's disease. Curr. Op. Pharmacol., 3, 54-61.
11. Calabresi, P., Centonze, D. & Bernardi, G. (2000) Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci., 23, S57-S63.
12. Carlsson, M. & Carlsson, A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci., 13, 272-276.
13. Cenci, M.A., Lee, C.S. & Björklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694-2706.
14. Chase, T.N. & Oh, J.D. (2000a) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci., 23, S86-S91.
15. Chase, T.N. & Oh, J.D. (2000b) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol., 47, S122-S129.
16. Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A. & Gilula, N.B. (1996) Molecular characterization of an enzyme that degrades neuro-modulatory fatty-acid amides. Nature, 384, 83-87.
17. D'Ambra, T.E., Estep, K.G., Bell, M.R., Eissenstat, M.A., Josef, K.A., Ward, S.J., Haycock, D.A., Baizman, E.R., Casiano, F.M. & Beglin, N.C. (1992) Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl) indole agonists of the cannabinoid receptor. J. Med. Chem., 35, 124-135.
18. Désarnaud, F., Cadas, H. & Piomelli, D. (1995) Anandamide amidohydrolase activity in rat brain microsomes: Identification and partial characterization. J. Biol. Chem., 270, 6030-6035.
19. Devane, W., Hanus, L., Breuer, A., Pertwee, R., Stevenson, L., Griffin, G., Gibson, D., Mandelbaum, D., Etinger, A. & Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
20. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C. & Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
21. Di Marzo, V., Hill, M.P., Bisogno, T., Crossman, A.R. & Brotchie, J.M. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J., 14, 1432-1438.
22. Felder, C.C., Nielsen, A., Briley, E.M., Palkovits, M., Priller, J., Axelrod, J., Nguyen, D.N., Richardson, J.M., Riggin, R.M., Koppel, G.A., Paul, S.M. & Becker, G.W. (1996) Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett., 393, 231-235.
23. Fox, S.H., Henry, B., Hill, M., Crossman, A. & Brotchie, J. (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord., 17, 1180-1187.
24. 1 dopamine receptor function: evidence for a novel pathway for receptor dephosphorylation. Mol. Pharmacol., 59, 310-321.
25. Gerdeman, G. & Lovinger, D.M. (2001) CB1 cannabinoid receptor inhibit synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol., 85, 468-471.
26. Gerdeman, G.L., Ronesi, J. & Lovinger, D.M. (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neurosci., 5, 446-451.
27. Gerfen, C.R. (1992) The neostriatal mosaic: multiple levels of compartmental organization. Annu. Rev. Neurosci., 15, 285-320.
28. Gerfen, C.R. (2000) Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci., 23, S64-S70.
29. Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J. & Sibley, D.R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 250, 1429-1432.
30. Gerfen, C.R., Miyachi, S., Paletzki, R. & Brown, P. (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci., 22, 5042-5054.
31. Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodríguez de Fonseca, F., Navarro, M. & Piomelli, D. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosci., 2, 358-363.
32. Giuffrida, A., Rodríguez de Fonseca, F. & Piomelli, D. (2000) Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal. Biochem., 280, 87-93.
33. Glass, M., Dragunow, M. & Faull, R.L.M. (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 77, 299-318.
34. Glass, M. & Felder, C.C. (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci., 17, 5327-5333.
35. Gonzalez, S., Cascio, M.G., Fernandez-Ruiz, J., Fezza, F., Di Marzo, V. & Ramos, J.A. (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res., 954, 73-81.
36. Graybiel, A.M., Aosaki, T., Flaherty, A.W. & Kimura, M. (1994) The basal ganglia and adaptive motor control. Science, 265, 1826-1831.
37. Graybiel, A.M., Canales, J.J. & Capper-Loup, C. (2000) Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci., 23, S71-S77.
38. Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernanrdi, G., Finazzi-Agro, A. & Maccarrone, M. (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci., 22, 6900-6907.
39. Hansen, H.H., Schmid, P.C., Bittigau, P., Lastres-Becker, I., Berrendero, F., Manzanares, J., Ikonomidou, C., Schmid, H.H.O., Fernandez-Ruiz, J. & Hansen, H.S. (2001) Anandamide, but not 2-arachidonylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem., 78, 1415-1427.
40. Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R. & Rice, K.C. (1990) Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA, 87, 1932-1936.
41. Hermann, H., Marsicano, G. & Lutz, B. (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience, 109, 451-460.
42. Hirsch, E.C., Périer, C., Orieux, G., François, C., Féger, J., Yelnik, J., Vila, M., Levy, R., Tolosa, E.S., Concepcio, M., Trinidad Herrero, M., Obeso, J.A. & Agid, Y. (2000) Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci., 23, S78-S85.
43. Hohmann, A.G. & Herkenham, M. (2000) Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse, 37, 71-80.
44. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K. & Martin, B.R. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
45. Hu, X.T., Wachtel, S.R., Galloway, M.P. & White, F.J. (1990) Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. J. Neurosci., 10, 2318-2329.
46. Huang, K.-X. & Walters, J.R. (1994) Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostfiatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output. J. Pharmacol. Exp. Ther., 271, 1434-1443.
47. 3 receptors by G protein-coupled receptor kinases and β-arrestins. J. Biol. Chem., 276, 37409-37414.
48. La Hoste, G.J., Yu, J. & Marshall, J.F. (1993) Striatal fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity. Proc. Natl Acad. Sci. USA, 90, 7451-7455.
49. Lastres-Becker, I., Fezza, F., Cebeira, M., Bisogno, T., Ramos, J.A., Milone, A., Fernandez-Ruiz, J. & Di Marzo, V. (2001) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport, 12, 2125-2129.
50. Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N. & Cenci, M.A. (2002) Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci., 15, 120-132.
51. Masserano, J.M., Karoum, F. & Wyatt, R.J. (1999) SR141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav. Pharmacol., 10, 429-432.
52. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R., Pertwee, R.G., Griffin, G., Bayewitch, M., Barg, J. & Vogel, Z. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90.
53. Meschler, J.P., Conley, T.J. & Howlett, A.C. (2000) Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol. Biochem. Behav., 67, 567-573.
54. Meschler, J.P. & Howlett, A.C. (2001) Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacol., 40, 918-926.
55. 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Res., 710, 234-240.
56. Moore, H. & Grace, A.A. (2002) A role for electrotonic coupling in the striatum in the expression of dopamine receptor-mediated stereotypies. Neuropsychopharmacology, 27, 980-992.
57. O'Dell, S.J. & Marshall, J.F. (1996) Chronic L-DOPA alters striatal NMDA receptors in rats with dopaminergic injury. Neuroreport, 7, 2457-2461.
58. Obeso, J.A., Olanow, C.W. & Nutt, J.G. (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci., 23, S2-S7.
59. Onn, S.P. & Grace, A.A. (1994) Dye coupling between rat striatal neurons recorded in vivo: compartmental organization and modulation by dopamine. J. Neurophysiol., 71, 1917-1934.
60. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R. & Shohami, E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413, 527-531.
61. Rodríguez de Fonseca, F., Villanúa, M.A., Munoz, R.M., San-Martin-Clark, O. & Navarro, M. (1995) Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats. Neuroendocrinology, 61, 714-721.
62. Romero, J., Garcia, L., Cebeira, M., Zadrozny, D., Fernandez-Ruiz, J.J. & Ramos, J.A. (1995) The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behaviour: role of nigrostriatal dopaminergic neurons. Life Sci., 56, 2033-2040.
63. Sañudo-Peña, M.C., Force, M., Tsou, K., Miller, A.S. & Walker, J.M. (1998) Effects of intrastriatal cannabinoid on rotational behavior in rats: interactions with the dopaminergic system. Synapse, 30, 221-226.
64. Sañudo-Peña, M.C. & Walker, J.M. (1998) Effects of intrapallidal cannabinoids on rotational behaviour in rats: interactions with the dopaminergic system. Synapse, 28, 27-32.
65. 3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra in rat. Neurosci. Lett., 72, 265-271.
66. Schmid, P.C., Krebsbach, R.J., Perry, S.R., Dettmer, T.M., Maasson, J.L. & Schmid, H.H.O. (1995) Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett., 375, 117-120.
67. Schmid, P.C., Zuzarte-Augustin, M.L. & Schmid, H.H.O. (1985) Properties of rat liver N-acylethanolamine amidohydrolase. J. Biol. Chem., 260, 14145-14149.
68. Sieradzan, K.A., Fox, S.H., Hill, M., Dick, J.P.R., Crossman, A.R. & Brotchie, J.M. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology, 57, 2108-2111.
69. Starr, M.S. (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse, 19, 264-293.
70. Stella, N., Schweitzer, P. & Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388, 773-778.
71. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. & Waku, K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 89-97.
72. Venance, L., Piomelli, D., Glowinski, J. & Giaume, C. (1995) Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature, 376, 590-594.
73. Waszczak, B.L., Lee, E.K., Tamminga, C.A. & Walters, J.R. (1984) Effect of dopamine system activation on substantia nigra pars reticulata output neurons: variable single-unit responses in normal rats and inhibition in 6-hydroxydopamine-lesioned rats. J. Neurosci., 4, 2369-2375.
74. Yang, H.T., Karoum, F., Felder, C., Badger, H., Wang, T.L. & Markey, S.P. (1999) GC/MS analysis of anandamide and quantification of N-arachidonoylphosphatidylethanolamides in various brain regions, spinal cords, testis, and spleen of the rat. J. Neurochem., 72, 1959-1968.
75. Zeng, B.Y., Dass, B., Owen, A., Rose, S., Cannizzaro, C., Tel, B.C. & Jenner, P. (1999) Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett., 276, 71-74.